研究目的
To develop a novel combination nanoplatform for synergistic chemo-photodynamic therapy using porphyrin-grafted lipid (PGL) NPs to encapsulate doxorubicin (DOX).
研究成果
The PGL-DOX NPs combined chemo-photodynamic nanoplatform may serve as a potential candidate for cancer theranostics.
研究不足
The challenges imposed by limited drug loading capacity and complex synthesis process of organic nanoparticles (NPs) have seriously impeded advances in chemo-photodynamic combination therapy.
1:Experimental Design and Method Selection:
A rapid injection method was used to prepare porphyrin-grafted lipid (PGL) NPs. The self-assembled PGL NPs were used to encapsulate DOX via a pH-gradient loading protocol.
2:Sample Selection and Data Sources:
HeLa and PC3 cell lines were used for in vitro studies, and a xenograft mouse model was used for in vivo studies.
3:List of Experimental Equipment and Materials:
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2k), cholesterol, dipalmitoyl-sn-glycero-3-phosphocholine (DSPC), and other organic reagents were used.
4:Experimental Procedures and Operational Workflow:
PGL NPs were prepared and loaded with DOX. The therapeutic efficacy was validated both in vitro and in vivo.
5:Data Analysis Methods:
Spectrophotometric analysis, fluorescence measurements, and flow cytometry were used for data analysis.
独家科研数据包,助您复现前沿成果,加速创新突破
获取完整内容